Teva (ADR) (TEVA)
Combines global generics scale with innovative neuroscience and immunology medicines.
$39.38
vs last close−0.14 (−0.35%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
$0.70
Revenue estimate
$4.27B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Jan '25May '25Jul '25Nov '25Jan '26Apr '26Jul '26Nov '26
Reported$0.71$0.52$0.66$0.78$0.96$0.53$0.02Pending
Estimate$0.69$0.47$0.63$0.68$0.65$0.50$0.08$0.70
Surprise+2.9%+10.6%+4.8%+14.7%+47.7%+6.0%−75.0%—
RevenueReportedEstimate
Jan '25May '25Jul '25Nov '25Jan '26Apr '26Jul '26Nov '26
Reported$4.23B$3.89B$4.18B$4.48B$4.71B$3.98B$4.14BPending
Estimate$4.10B$4.38B$4.36B$4.45B$4.32B$3.79B$4.08B$4.27B
Surprise+3.0%−11.2%−4.3%+0.6%+9.1%+5.1%+1.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.88 | — | — |
| Sep 2027 | $0.83 | — | — |
| Jun 2027 | $0.73 | — | — |
| Mar 2027 | $0.62 | — | — |
| Dec 2026 | $0.73 | — | — |
| Nov 2026 | $0.70 | — | — |
| Jul 2026 | $0.08 | $0.02 | −75.0% |
| Apr 2026 | $0.50 | $0.53 | +6.0% |
| Jan 2026 | $0.65 | $0.96 | +47.7% |
| Nov 2025 | $0.68 | $0.78 | +14.7% |
| Jul 2025 | |||
| May 2025 | |||
| Jan 2025 | |||
| Nov 2024 | |||
| Jul 2024 | |||
| May 2024 | |||
| Jan 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Jul 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.88 | — | — | $4.50B | — | — | — |
| Sep 2027 | $0.83 | — | — | $4.47B | — | — | — |
| Jun 2027 | $0.73 | — | — | $4.27B | — | — | — |
| Mar 2027 | $0.62 | — | — | $3.99B | — | — | — |
| Dec 2026 | $0.73 | — | — | $4.26B | — | — | — |
| Nov 4, 2026 | $0.70 | — | — | $4.27B | — | — | — |
| Jul 29, 2026 | $0.08 | $0.02 | −75.0% | $4.08B | $4.14B | +1.5% | +9.6% |
| Apr 29, 2026 | $0.50 | $0.53 | +6.0% | $3.79B | $3.98B | +5.1% | +11.9% |
| Jan 28, 2026 | $0.65 | $0.96 | +47.7% | $4.32B | $4.71B | +9.1% | +2.1% |
| Nov 5, 2025 | $0.68 | $0.78 | +14.7% | $4.45B | $4.48B | +0.6% | +20.2% |
| Jul 30, 2025 | |||||||
| May 7, 2025 | |||||||
| Jan 29, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Jul 31, 2024 | |||||||
| May 8, 2024 | |||||||
| Jan 31, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 10, 2023 | |||||||
| Feb 8, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Jul 26, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 9, 2022 | |||||||
| Oct 27, 2021 | |||||||
| Jul 28, 2021 | |||||||
| Apr 28, 2021 | |||||||
| Feb 10, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 2, 2019 | |||||||
| Feb 13, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Feb 8, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 11, 2017 | |||||||
| Feb 13, 2017 | |||||||
| Nov 15, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 11, 2016 | |||||||
| Oct 29, 2015 | |||||||
| Jul 30, 2015 |